ESR1 and breast cancer: Interestingly, Foxf2 expression was significantly higher in more aggressive tumor subtypes, such as ER– compared with ER+, triple-negative compared with all other subtypes, and in claudin-low tumors (the breast cancer subtype associated with an EMT signature), compared with all others (Fig. 6h).